

United States Senate
WASHINGTON, DC 20510

November 6, 2025

The Honorable Robert F Kennedy Jr.
Secretary
U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201

Dear Secretary Kennedy,

The recently announced drug pricing arrangements the Trump Administration has entered into with Pfizer and AstraZeneca, as well as the newly unveiled "TrumpRx" platform¹, have potentially negative implications for patients, taxpayers, and existing state and federal drug pricing programs.²

The Administration's announcement of a new Most Favored Nation (MFN)-style deal with Pfizer and AstraZeneca included much fanfare but few details about how the program will be implemented.³

State Medicaid programs and safety net providers rely on the Medicaid Drug Rebate Program to ensure vulnerable patients get the lowest prices. The introduction of a new, preferential pricing arrangement with individual manufacturers, absent a statutory framework, threatens to undermine these longstanding programs.

To better understand the scope and potential consequences of the Pfizer and AstraZeneca deals, please provide answers to the following:

1. How will state Medicaid programs access Pfizer and AstraZeneca medications included in the announced MFN agreement? Will they be required to opt into a new purchasing structure, or will pricing automatically apply?

¹ The White House, *TrumpRx* (online at <https://trumptrx.gov/>) (accessed October 10, 2025).

² The White House, *Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients* (Sept. 30, 2025) (online at <https://www.whitehouse.gov/fact-sheets/2025/09/fact-sheet-president-donald-j-trump-announces-first-deal-to-bring-most-favored-nation-pricing-to-american-patients/>); AstraZeneca, *AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients* (October 10, 2025) (online at <https://www.astrazeneca-us.com/content/az-us/media/press-releases/2025/astrazeneca-announces-historic-agreement-with-us-government-to-lower-the-cost-of-medicines-for-american-patients.html>)

³ The Wall Street Journal, *White House Unveils 'TrumpRx' Drug-Buying Site and a Pfizer Pricing Deal* (Sept. 30, 2025) (online at https://www.wsj.com/health/pharma/white-house-to-announce-trump-rx-drug-buying-website-and-deal-with-pfizer-8c42e5cb?gaa_at=eafs&gaa_n=ASWzDAjTGha6Qjh4XxsySVdQSghlO8DwOS9Borop7Mp6qUQprEFdZz1lCceR&gaa_ts=68e7c9e9&gaa_sig=iOreD2QJUX_YocoYtEs0tFoLqA39jzgieD4xDKlkKIv56CVvmjGEmImLBmQ4I13z2KATkrhpKpLg_ccRx3vC8Q%3D%3D).

2. Which Pfizer and AstraZeneca medications will be included in the Medicaid component of the MFN deal? What criteria are being used to select these drugs? Are drugs marketed under affiliate and subsidiary labels included in these agreements?
3. What countries were used to determine the MFN reference price?
4. How do the prices under the MFN deal compare to the average net prices state Medicaid programs currently pay after rebates?
5. Will this agreement affect the rebates manufacturers are required to provide under the Medicaid Drug Rebate Program?
6. Will these deals reduce or replace existing statutory rebates?
7. How will these deals interfere with existing statutory rebates?
8. How will these deals affect Medicaid statutory rebates that are paid to Treasury?
9. Do these deals waive any part of the Medicare Drug Rebate Program agreements?
10. How will these arrangements affect the 340B Drug Pricing Program, which supports safety-net providers serving vulnerable communities?
11. Will covered entities still be able to access upfront 340B pricing for medications included in the MFN arrangements?

Additionally, the Administration has announced a new initiative called “TrumpRx,” promising “deep discounts” on brand-name medications for American consumers.⁴ No detailed information has been provided regarding the scope, structure, or legal authority for this program.

While the announcement of TrumpRx emphasized affordability and access, direct-to-patient sales programs help only a fraction of patients—those who can afford to buy their drugs out of pocket.⁵ Additionally, these direct-to-consumer discount programs do nothing to address long-term costs.⁶

BlinkRx—a direct-to-patient sales platform of which President Trump’s son, Donald Trump Jr., is a board member—will reportedly be facilitating the TrumpRx program⁷. The *Wall Street Journal* recently reported President Trump’s upcoming “Future of Pharmaceuticals” summit will be co-hosted by BlinkRx and 1789 Capital, a venture capital firm in which Mr. Trump Jr. is a

⁴ The Wall Street Journal, *White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal* (Sept. 30, 2025) (online at https://www.wsj.com/health/pharma/white-house-to-announce-trumprx-drug-buying-website-and-deal-with-pfizer-8c42e5cb?gaa_at=eafs&gaa_n=ASWzDAjTGha6Qjh4XxsySVdOSghlO8DwOS9Borop7Mp6qUQprEFdZz1lCceR&gaa_ts=68e7c9e9&gaa_sig=iOreD2QJUX_YocoYtEs0tFoLqA39jzgieD4xDKlkKlv56CVvmjGEmImLBmQ4l13z2KATkrhpKpLg_ccRx3vC8Q%3D%3D).

⁵ Stat News, *Why Direct-to-Consumer Sales are Unlikely to Significantly Lower Drug Costs*, (Aug. 19, 2025) (online at <https://www.statnews.com/2025/08/19/direct-to-consumer-drug-costs-pharma-analysis/#:~:text=The%20reality%2C%20though%2C%20is%20far.patients%20can%20get%20through%20insurance.>).

⁶ Axios, *More Pharma Giants Embrace Direct to Consumer Sales* (Aug. 4, 2025) (online at <https://www.axios.com/2025/08/04/pharma-direct-sales-lower-drug-prices>)

⁷ The Wall Street Journal, *Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit* (October 7, 2025) (online at <https://www.wsj.com/health/pharma/trumprx-drug-companies-blinkrx-2b6e1761>).

partner. The firm invested in BlinkRx less than a year ago.⁸ These connections raise questions about potential conflicts of interest between TrumpRx and the Trump family's business dealings.⁹

In light of this, we request answers to the following questions:

1. What is the role and purpose of TrumpRx?
2. How will medications on TrumpRx be accessed by consumers?
3. What specific drugs will be offered under the TrumpRx program?
4. Are these medications limited to Pfizer and AstraZeneca products, or will other manufacturers participate?
5. Will patients with Medicare coverage be able to access TrumpRx discounts? How?
6. Will patients enrolled in Medicaid be able to access TrumpRx discounts? How?
7. What compliance measures will be in place to ensure that TrumpRx is not violating Stark Law and the Anti-Kickback Statute?
8. How will patients with commercial insurance plans access TrumpRx discounts?
9. Will beneficiaries be required to use specific pharmacies or platforms? If so, will this differ based on insurance provider?
10. How are prices being set under TrumpRx? Are prices based on international reference pricing, average manufacturer price (AMP), or negotiated rates? Will prices be posted publicly without consumers having to sign up, pay a member fee, or provide health information to access them?
11. What impact will these prices have on Medicaid best price?
12. How will TrumpRx interact with BlinkRx?¹⁰
13. If BlinkRx is being considered as a contractor or vendor for TrumpRx, will they receive any form of payment from the federal government? If yes, how is that arrangement being vetted for possible ethics and conflict of interest violations?
14. What contractual relationship exists between Blink, HHS, GSA, OMB, and/or Treasury?
15. Will TrumpRx function as a pharmacy benefit manager (PBM), pharmacy, provider, and/or telehealth platform? If a PBM, how will TrumpRx comply with existing PBM transparency and reporting requirements under federal law? If a provider or pharmacy, how will TrumpRx comply with existing transparency, reporting, and compliance requirements under federal law?

⁸ Bloomberg, 'Anti-Woke' 1789 Capital Bets on Drug Startup BlinkRx, (Nov. 15, 2024) (online at <https://www.bloomberg.com/news/articles/2024-11-15/malik-s-anti-woke-1789-capital-bets-on-drug-startup-blinkrx>).

⁹ The Wall Street Journal, *White House Unveils 'TrumpRx' Drug-Buying Site and a Pfizer Pricing Deal* (Sept. 30, 2025) (online at https://www.wsj.com/health/pharma/white-house-to-announce-trumprx-drug-buying-website-and-deal-with-pfizer-8c42e5cb?gaa_at=eafs&gaa_n=ASWzDAjTGha6Qjh4XxsySVdQSghIQ8DwOS9Borop7Mp6qUQprEFdZz1lCceR&gaa_ts=68e7c9e9&gaa_sig=iOreD2QJUX_YocoYtEs0tFoLqA39jzgieD4xDKlkKlv56CVvmjGEmImLBmQ4I13z2KATkrhpKpLg_ccRx3vC8Q%3D%3D).

¹⁰ The Wall Street Journal, *Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit* (October 7, 2025) (online at <https://www.wsj.com/health/pharma/trumprx-drug-companies-blinkrx-2b6e1761>).

Given the wide-reaching implications for Medicare and Medicaid beneficiaries, and the 340B safety-net covered entities, it is imperative that the Department provide Congress and the public with immediate transparency regarding the structure, impact, and legality of these initiatives.

We request answers to these questions by November 21, 2025.


Sincerely,



Peter Welch
United States Senator




Amy Klobuchar
United States Senator



Ben Ray Lujan
United States Senator



Elizabeth Warren
United States Senator



Jeffrey A. Merkley
United States Senator



Angela D. Alsobrooks
United States Senator



Bernard Sanders
United States Senator